Added to YB: 2026-03-31
Pitch date: 2026-03-28
LNSR [bullish]
LENSAR, Inc.
-5.32%
current return
Author Info
No bio for this author
Company Info
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System.
Market Cap
$72.5M
Pitch Price
$6.20
Price Target
18.00 (+197%)
Dividend
N/A
EV/EBITDA
-20.33
P/E
-1.40
EV/Sales
1.22
Sector
Health Care Equipment and Supplies
Category
special_situation
LENSAR: Alcon Wanted to Pay $14. The Market Says $5.50. Someone Is Wrong
LNSR: Alcon offered $14/sh ($454M total) after months of DD; FTC blocked deal Mar 2026, stock crashed to $5.50 on arb liquidation in illiquid micro-cap. Business stronger now: TTM rev $59M (+11%), 79% recurring, 425 systems installed (+77% ALLY YoY), $27M cash ($24M net), $10M Alcon deposit retained, 2.5yr runway. EV/Sales 2.1x vs Alcon's 6.2x. Q2/Q3 slowdown entirely M&A-driven (system sales chilled), recurring rev grew +13-22%. Path to positive FCF FY26, $25M by FY30. Risks: illiquidity, standalone scaling, 15.2M warrants. Fair value $10 (82% upside), bull case $15-18.
Read full article (8 min)